viernes, 3 de marzo de 2017

Translational Oncology

Translational Oncology

Biomed Central

Translational Oncology

Global cancer occurrence has increased from 12.7 million new cases in 2008 to 14.1 million in 2012, and it is expected that the incidence will rise by around 70% over the next two decades. A comprehensive understanding of the pathophysiological processes underlying cancer development is of utmost importance for the development of detection techniques, diagnostic and prognostic markers, new therapies, risk assessment tools, and cancer prevention strategies.
Characterizing the molecular basis of cancer is a rapidly progressing area of research, with many laboratory discoveries translating into important advances that impact patient care. Our new cross-journal article collection on Translational Oncology aims to showcase the results of novel research findings that bridge the gap between basic science and cancer medicine.
The journals included in this collection are BMC MedicineBMC CancerCancers of the Head and NeckClinical Sarcoma Research and Journal of Experimental and Clinical Cancer Research. We are seeking submissions of research articles that provide important developments in cancer research. Preclinical studies should provide a significant advance in knowledge, and have clear potential for strong clinical impact. This collection will also include invited reviews, debates and commentaries. If you have any original research you would like us to consider for inclusion our Translational Oncology collection, please submit directly to your journal of choice, and state within your cover letter that you want the submission to be considered for this Translational Oncology article collection.
Guest Edited by Prof Tommaso Dragani (Fondazione IRCCS Istituto Nazionale dei Tumori, Italy), the series is now accepting submissions of research articles that provide important developments in cancer research. 
Please choose from the following list of journals to submit your article to:

    Molecular chess? Hallmarks of anti-cancer drug resistance

    The development of resistance is a problem shared by both classical chemotherapy and targeted therapy. Patients may respond well at first, but relapse is inevitable for many cancer patients, despite many impro...
    Ian A. Cree and Peter Charlton
    BMC Cancer 2017 17:10
    Published on: 5 January 2017

    Exosomes play an important role in the process of psoralen reverse multidrug resistance of breast cancer

    Release of exosomes have been shown to play critical roles in drug resistance by delivering cargo. Targeting the transfer of exosomes from resistant cells to sensitive cells may be an approach to overcome some...
    Xiaohong Wang, Chengfeng Xu, Yitong Hua, Leitao Sun, Kai Cheng, Zhongming Jia, Yong Han, Jianli Dong, Yuzhen Cui and Zhenlin Yang
    Journal of Experimental & Clinical Cancer Research 2016 35:186
    Published on: 1 December 2016

    Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma

    Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the sa...
    Shanthini M. Crusz, Yen Zhi Tang, Shah-Jalal Sarker, Warner Prevoo, Irfan Kiyani, Luis Beltran, John Peters, Anju Sahdev, Axel Bex, Thomas Powles and Marco Gerlinger
    BMC Medicine 2016 14:185
    Published on: 14 November 2016

    Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone

    The spatial relationship of glioblastoma (GBM) to the subventricular zone (SVZ) is associated with inferior patient survival. However, the underlying molecular phenotype is largely unknown. We interrogated an ...
    Christine Jungk, Andreas Mock, Janina Exner, Christoph Geisenberger, Rolf Warta, David Capper, Amir Abdollahi, Sara Friauf, Bernd Lahrmann, Niels Grabe, Philipp Beckhove, Andreas von Deimling, Andreas Unterberg and Christel Herold-Mende
    BMC Medicine 2016 14:170
    Published on: 26 October 2016

    Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

    While clinical outcomes following immunotherapy have shown an association with tumor mutation load using whole exome sequencing (WES), its clinical applicability is currently limited by cost and bioinformatics...
    Jason Roszik, Lauren E. Haydu, Kenneth R. Hess, Junna Oba, Aron Y. Joon, Alan E. Siroy, Tatiana V. Karpinets, Francesco C. Stingo, Veera Baladandayuthapani, Michael T. Tetzlaff, Jennifer A. Wargo, Ken Chen, Marie-Andrée Forget, Cara L. Haymaker, Jie Qing Chen, Funda Meric-Bernstam…
    BMC Medicine 2016 14:168
    Published on: 25 October 2016

    Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells

    High-grade non-muscle invasive bladder cancer (NMIBC) has a high risk of recurrence and progression to muscle-invasive forms, which seems to be largely related to the presence of tumorigenic stem-like cell pop...
    Margarida Ferreira-Teixeira, Daniela Paiva-Oliveira, Belmiro Parada, Vera Alves, Vitor Sousa, Obinna Chijioke, Christian Münz, Flávio Reis, Paulo Rodrigues-Santos and Célia Gomes
    BMC Medicine 2016 14:163
    Published on: 21 October 2016

    Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening

    Non-invasive prenatal testing (NIPT) identifies fetal aneuploidy by sequencing cell-free DNA in the maternal plasma. Pre-symptomatic maternal malignancies have been incidentally detected during NIPT based on a...
    Paul A. Cohen, Nicola Flowers, Stephen Tong, Natalie Hannan, Mark D. Pertile and Lisa Hui
    BMC Medicine 2016 14:126
    Published on: 24 August 2016
  8. FORUM

    Major milestones in translational oncology

    Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from geno...
    Tommaso A. Dragani, Antoni Castells, Vathany Kulasingam, Eleftherios P. Diamandis, Helena Earl, Wade T. Iams, Christine M. Lovly, J. P. Michiel Sedelaar and Jack A. Schalken
    BMC Medicine 2016 14:110
    Published on: 28 July 2016

No hay comentarios:

Publicar un comentario